Suven Pharmaceuticals acquires majority stake in NJ Bio, strengthens US presence
Suven Pharmaceuticals Limited, a technology-focused contract development and manufacturing organisation (CDMO), has announced the acquisition of a controlling 56% stake in NJ Bio Inc., a ... Read More
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More